AAVBC

American Academy of Value Based Care

Inflammatory Polyarthropathy

Quick Reference Guide

2026

AAVBC Inflammatory Polyarthropathy Quick Reference Guide

Table of Contents

1. CLINICAL SNAPSHOT

Definition: Inflammatory polyarthropathy is characterized by inflammation that affects five or more joints, causing pain, swelling, warmth, tenderness, redness, and prolonged morning stiffness (e.g., >30 to 45 minutes).[1]

ICD-10 Codes: M05 Seropositive Rheumatoid Arthritis (M05.0-M05.9); M06 Other Rheumatoid Arthritis (M06.0-M06.9), including *Inflammatory polarthropathy (M06.4)*; M07 Psoriatic and enteropathic arthropathies (M07.0-M07.6), M08 Juvenile arthritis (M08.0-M08.9), M09 Juvenile arthritis in diseases classified elsewhere (M09.0-M09.8); M10 Gout (M010-M10.9); M11 Other crystal arthropathies (M11.0-M11.9); M12 Other specific arthropathies (M12.0-M12.8); M13 Other arthritis (M13.0-M13.9); M14 Arthropathies in other diseases classified elsewhere (M14.0-M14.8)[2]

HCC/RAF V28 mapping: M05-M09 (Inflammatory polyarthropathies) map to **HCC 93 with RAF 0.617**; **M010-M014** do not map to an HCC

Prevalence: ~53.2M (21.2%) US adults have arthritis (includes non-inflammatory arthritis);[3] Annual incidence of inflammatory arthritis ranges from 115 to 271 per 100,000 adults in the US;[4] ~Cost of arthritis ranged from $1862 to $14,021 per member per year (includes non-inflammatory arthritis).[5]

No US data on prevalence or cost burden of polyinflammatory arthritis alone.

2. RECOGNITION AND DIAGNOSIS

Medicare Screening/Diagnostic Workup[6–8]

There are **no routine screening requirements** for inflammatory polyarthritis.

Evaluation is initiated when a patient presents with **persistent joint swelling**, **inflammatory stiffness**, or **polyarticular pain**.[6]

Step 1: Confirm Inflammatory Pattern → History + Physical Examination

- Morning stiffness >30-60 minutes
- Visible synovitis
- Symmetric or small-joint involvement
- Five different joints involved
- Functional limitation

If inflammatory arthritis is suspected → proceed with laboratory evaluation.

Step 2: Laboratory Evaluation by Symptom Duration

Acute Presentation (≤6 Weeks)

Recommended Tests	Rationale
CBC	Assess anemia, leukocytosis
CRP, ESR	Identify systemic inflammation

Avoid broad serologic panels early unless clinical suspicion for systemic autoimmune disease is high. Many early inflammatory arthritides are seronegative in the initial weeks.

Chronic Symptoms (>6 Weeks)

Core Laboratory Panel	Purpose
CBC	Baseline hematologic assessment
CRP, ESR	Inflammatory activity
RF	Supports RA diagnosis
Anti-CCP	High specificity for RA
ANA	Screens for connective tissue disease

If ANA is positive, proceed selectively based on clinical features

Step 3: Targeted Autoimmune Evaluation (If ANA Positive or Systemic Features Present)

Antibody	Clinical Association
Anti-dsDNA	Strongly associated with SLE (high titers significant)
Anti-Sm	Highly specific for SLE
Anti-RNP	Mixed Connective Tissue Disease; may overlap with SLE
Anti-SSA/Ro, Anti-SSB/La	SLE and Sjögren's overlap
Anti-Scl-70	Systemic Sclerosis
Anti-Jo-1	Idiopathic Inflammatory Myopathies
ANCA (if vasculitis suspected)	Small-vessel vasculitis syndromes

Important: Order extended panels only when supported by systemic findings (rash, Raynaud, serositis, pulmonary symptoms, myositis, etc.). Broad untargeted testing increases false positives and diagnostic confusion.

Decision Tree



Diagnostic Workup

Clinical Assessment Key Differentials[6,9]

Condition	Typical Symptoms	Key Signs	Tests	Features
Rheumatoid arthritis	Persistent joint pain & stiffness (>6 weeks)	Swollen/tender small joints (MCP, PIP, wrists)	RF positive in many; Anti-CCP positive	Symmetric joint involvement
Inflammatory polyarthropathy	Persistent joint pain & stiffness (>6 weeks) in **5 or more joints**	Swollen/tender small joints (MCP, PIP, wrists)	RF negative; Anti-CCP can be positive	Symmetric joint involvement; commonly have systemic symptoms
Seronegative spondyloarthritides	Joint + tendon/enthesis pain	Dactylitis; sacroiliitis; nail changes	Often RF negative; HLA-B27+	Psoriasis or family history
SLE/systemic rheumatic diseases	Multisystem symptoms (rash, pleurisy, photosensitivity)	More tenderness than swelling	ANA positive; autoantibodies (ENA, anti-dsDNA), cytopenias Negative ANA does not rule out SLE	Non-erosive arthritis
Maturity-onset seronegative synovitis (MOSS)	Sudden-onset stiffness/pain in older adults	Wrist & shoulder involvement	RF/ANA negative; high ESR	Steroid responsive
Crystal-induced arthritis (gout/CPPD)	Episodic flares; may become polyarticular	Tophi possible	Uric acid ↑ (not always)	Crystals on aspiration
Inflammatory osteoarthritis	Pain in DIP/PIP/CMC joints	Heberden/Bouchard nodes	Labs usually normal	X-ray OA changes

Abbreviations: MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; DIP, distal interphalangeal joint; PIP, proximal interphalangeal joint; CMC, carpometacarpal joint

Imaging & Ultrasound[10]

Do not perform routine imaging or ultrasound. Imaging is most useful for identifying evidence of disease activity when the clinical assessment is not clear.

Radiologic evidence of disease progression (e.g., periarticular osteopenia, joint space narrowing, or bone erosions) indicates that the current DMARD regimen is inadequate and requires modification. However, coexistent osteoarthritis may also account, in part, for joint space narrowing in older patients with concurrent inflammatory polyarthropathy. Musculoskeletal ultrasound and MRI may be used to confirm the presence of synovitis when the joint examination is equivocal.

Laboratory Assessments[6,7,9–12]

Condition	ESR (Raised)	CRP (Raised)	Anti-CCP	HLA-B27	RF (+)	ANA (+)	ENA (+)	Anti-dsDNA (+)
Rheumatoid Arthritis	Often	Often	+	−	Often	Sometimes	−	−
AxSpA (Axial Spondyloarthritis)	Often	Often	−	+	Sometimes	Sometimes	−	−
PsPA (Peripheral spondyloarthritis)	Often	Often	−	+	−	Sometimes	−	−
PsA (Psoriatic Arthritis)	Often	Often	−	+	−	Sometimes	−	−
Inflammatory polyarthropathy	Often	Often	Sometimes	−	−	−	−	−
Systemic Lupus Erythematosus	Sometimes	Sometimes	−	−	Sometimes	Very Often	Very Often	+
Polymyalgia Rheumatica	Very Often	Very Often	−	−	Sometimes	Sometimes	−	−
Osteoarthritis	Sometimes	Sometimes	−	−	Sometimes	Sometimes	−	−
Fibromyalgia	Very Rarely	Very Rarely	−	−	Sometimes	Sometimes	−	−

Subtle Early Signs in Older Adults >65 (Extra-articular symptoms)

- **Weakness** → Consider neurologic or myopathic disorder
- **Skin involvement/Rash** → May suggest Psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), Still's disease, or vasculitis
- **Multisystem involvement (fatigue, oral or nasal ulcers, dry eyes/mouth)** → Can be seen in systemic lupus erythematosus (SLE), Sjögren's disease (SjD), systemic sclerosis (SSc), mixed connective tissue disease (MCTD)
- **Fever** → Raises suspicion septic arthritis, enteric arthritis and a subset of rheumatic diseases, including SLE, Still's disease, vasculitis, and crystalline arthropathy

Geriatric Risk Factors[13–16]

Factor	Risk Signal
Family history	**~40–50% risk** for seropositive RA, being strongest in first-degree relatives
Smoking	**Low exposure (1 to 10 pack-years):** The risk increases by about **26%** (RR = ~1.26) **Heavy exposure (over 20 pack-years):** The risk **doubles** (RR = ~2.0) compared to never-smokers
Sex	~two-thirds of individuals who develop RA are women The cumulative risk of developing RA in adult population has been estimated at 3.6% for women and 1.7% for men
Abbreviations: RR, Relative Risk	

Red Flags[17,18]

Red Flag	Description	Urgent Concern	Required Action
Septic Arthritis (Infection)	Severe, rapidly worsening pain in a single joint (e.g., knee, hip, shoulder), often with fever, chills, and inability to bear weight or move the joint	Joint destruction and sepsis. Bacterial infection can destroy the joint cartilage within hours and spread systemically	Immediate joint aspiration to diagnose and confirm bacteria IV antibiotics started immediately
Acute Spinal Cord Compression	New onset of severe neck or back pain in a patient with inflammatory arthritis (especially RA or Ankylosing Spondylitis), accompanied by: Bowel/bladder incontinence or retention, numbness in the saddle area, or new, rapid muscle weakness	Neurological Emergency. This suggests spinal instability (Atlantoaxial Subluxation in RA) or acute spinal inflammation (AS) causing cord compression	Emergency imaging (MRI) and Neurosurgical/Orthopedic consultation to prevent permanent paralysis
Acute Vasculitis/Organ Ischemia	New, severe, unexplained systemic symptoms such as sudden abdominal pain (bowel ischemia), sudden vision loss (optic nerve vasculitis), or new onset of severe headache/jaw pain (Giant Cell Arteritis)	Organ or Limb Loss. Severe systemic inflammation causing blood vessel blockage (vasculitis)	Immediate High-Dose IV Steroids to stop the inflammatory process and prevent irreversible damage (e.g., blindness)
Unexplained Pulmonary Symptoms	New or rapidly worsening shortness of breath, non-healing skin ulcers, or digital ischemia (fingertip pallor/necrosis	Severe pulmonary or systemic fibrosis/Infection can indicate interstitial lung disease or severe	Urgent chest imaging (HRCT) and assessment for oxygen support and aggressive immunosuppression

Red Flag	Description	Urgent Concern	Required Action
		systemic involvement (e.g., Lupus, Scleroderma)	
Rapidly Destructive Arthritis	Rapid radiological progression or clinical destruction of a joint despite treatment (rare, but seen in some severe RA or septic cases	Irreversible joint destruction within weeks	Aggressive escalation of disease-modifying therapy (DMARDs/Biologics) and possible surgical intervention

Diagnostic Thresholds

- **Joint Count** → **≥5 joints** demonstrating objective swelling (synovitis) or tenderness
- **Symptom Duration** → joint symptoms persisting for **≥6 weeks**

Clues to Dig Deeper

Category	Clinical Clue	What It Suggests	Immediate Clinical Focus
Joint Distribution and Exam Findings	Enthesitis (heel, Achilles)	Spondyloarthritis (e.g., PsA, AS)	Assess HLA-B27; image sacroiliac joints if axial symptoms present
	Dactylitis ("sausage digit")	Psoriatic Arthritis	Full skin and nail exam (psoriasis, nail pitting)
	DIP joint involvement	PsA vs Erosive OA	Evaluate for psoriasis; assess radiographic pattern
	Symmetric MCP/wrist synovitis	Rheumatoid Arthritis	RF, Anti-CCP; baseline hand/wrist X-rays
Age and Onset Pattern	Proximal stiffness (shoulders/hips) in ≥60	Polymyalgia Rheumatica	ESR/CRP; assess steroid responsiveness
	Insidious onset with proximal stiffness (elderly)	PMR vs Elderly-Onset RA	Inflammatory markers + synovitis exam
	Sudden acute onset with fever/systemic symptoms	SLE flare, Viral arthritis, Adult-Onset Still's Disease	Autoimmune labs; inflammatory markers; systemic evaluation
Systemic/Extra-Articular Features	Raynaud phenomenon + dyspnea/cough	Systemic sclerosis or SLE	ANA, ENA panel; evaluate pulmonary involvement (consider HRCT if indicated)
	GI symptoms (bloody diarrhea, chronic IBD)	Enteropathic Arthritis	Coordinate with Gastroenterology

Category	Clinical Clue	What It Suggests	Immediate Clinical Focus
Disease Course and Progression	Episodic/migratory pattern with full remission	Palindromic Rheumatism; Crystalline arthritis	Consider uric acid/CPPD evaluation; monitor evolution toward RA
	Rapidly destructive arthritis	Septic arthritis (urgent), aggressive RA, arthritis mutilans	Urgent joint aspiration; rule out infection first

Common Oversights

1. Misclassifying Non-Classical Presentations

- **Under-Recognizing Elderly-Onset RA (EORA):** EORA often presents as an acute, symmetrical **proximal polyarthritis** (affecting shoulders and hips) with prominent systemic symptoms (fever, malaise). This is often mistaken for **Polymyalgia Rheumatica (PMR)** or general aging
- **Missing Seronegative Disease:** Even with clear synovitis and inflammatory symptoms, Rheumatoid Arthritis (RA) or Psoriatic Arthritis (PsA) may be dismissed if Rheumatoid Factor (RF) and Anti-CCP antibodies are negative

2. Failure to Identify Systemic Clues

- **Neglecting Extra-Articular Symptoms:**
  - **Skin/Nail Psoriasis:** A patient may have mild, hidden psoriasis (e.g., on the scalp or in the gluteal cleft) that is missed, preventing the diagnosis of **Psoriatic Arthritis (PsA)**
  - **Gastrointestinal Symptoms:** Not linking joint pain to symptoms of diarrhea or abdominal pain, which points directly to **Enteropathic Arthritis**
- **Overlooking Enthesitis and Dactylitis:** These features are primary markers for **SpA** and **PsA**. They are often mistaken for common tendonitis or cellulitis

3. Misinterpretation of Labs and Imaging

- **Dismissing Normal Labs:** A normal ESR and CRP does **not** rule out inflammatory arthritis, especially in early or mild cases, or in conditions like Psoriatic Arthritis
- **Misinterpreting ANA:** Using a positive Antinuclear Antibody (ANA) test as the sole diagnostic criteria for Lupus. A low-titer ANA is common in healthy people; failure to follow up with specific tests (like ENA or Anti-dsDNA) can lead to over-diagnosis of **SLE**
- **Under-Utilizing Ultrasound: Musculoskeletal ultrasound** is often overlooked but can quickly and accurately detect early, subtle **synovitis** (joint lining inflammation) and **erosions** that guide diagnosis and treatment escalation

4. Focusing Only on Synovial Joints

- **Missing Proximal Girdle Involvement:** In PMR, the pain is peri-articular (around the joint) and affects muscles/tendons more than the joint itself. Focusing solely on identifying classic synovitis can lead to missing the PMR diagnosis

Key Differentials[1,6,7,11,12,19]

Consider the following differential diagnoses in patients with polyarticular joint pain. Monoarticular joint pain may indicate crystalline arthritis, lyme arthritis, septic arthritis. Oligoarticular pain may indicate spondyloarthritis.

System	Characteristic	Diagnoses to Consider
Constitutional	Sleep disorder	Fibromyalgia
Joint Distribution	1st metatarsophalangeal joint	Osteoarthritis, Gout
	Symmetric joint involvement (Digits 2 and 3, wrists, hips, elbows)	Rheumatoid Arthritis, Inflammatory Polyarthropathy (5 joints involved)
	Carpometacarpal joint	Osteoarthritis
	Distal interphalangeal joints	Osteoarthritis, Psoriatic Arthritis, Gout
	Digits 1 to 3 of hand	Carpal Tunnel Syndrome, Pseudogout
	Morning lower back pain > 1 hour	Spondyloarthritis
	Enthesitis (e.g., Achilles tendonitis)	Spondyloarthritis
	Proximal joint stiffness (i.e., shoulders and hips)	Polymyalgia Rheumatica
	Proximal muscle weakness (i.e., shoulders and hips)	Inflammatory Myopathy
Joints Characteristics	Triggering or locking of one or more digits of the hand	Stenosising Tenosynovitis
	Hyperextensible joints	Hypermobility Syndrome
	Numbness and/or tingling	Carpal Tunnel Syndrome, Neuropathy
	Joint pain remits spontaneously	Crystalline Arthritis, Palindromic Rheumatism
Infectious Disease	Recent sick contacts or viral syndrome	Viral Arthritis
	Other evidence of infection (e.g., fever, asthenia)	Septic Arthritis
	Lyme disease endemicity	Lyme Arthritis
Mucocutaneous	Dry mouth/eyes	Sjögren's Disease
	Malar rash (i.e., erythematous rash across nose and cheeks)	Systemic Lupus Erythematosus
Pulmonary	Dyspnea, cough	Inflammatory myopathy, systemic lupus erythematosus, scleroderma, sarcoidosis

System	Characteristic	Diagnoses to Consider
Vascular	Raynaud phenomenon (i.e., reversible digital ischemia)	Systemic lupus erythematosus, scleroderma
Gastrointestinal	Inflammatory bowel disease	Inflammatory bowel disease-associated arthritis
	Bloody bowel movements	Inflammatory bowel disease-associated arthritis

Comorbidity Screening[20–22]

Comorbidity	When to Initiate Screening	Recommended Frequency	Key Consideration
Cardiovascular Risk	At the time of initial diagnosis and periodically thereafter	At least every 5 years or whenever there is a significant change in disease activity or therapy	Uses established risk calculators (e.g., Framingham)
Osteoporosis (Bone Density)	Initial DXA Scan recommended for all RA patients, especially post-menopausal women and men aged	Repeat scan every 1 to 3 years, depending on the baseline T-score, ongoing glucocorticoid (steroid) use, and fracture history	High-risk patients on glucocorticoids (e.g., Prednisone) need more frequent monitoring
Tuberculosis (Latent TB)	**Prior to starting any Biologic** or targeted synthetic DMARD (tsDMARD), such as TNF inhibitors or JAK inhibitors	**Annual TB screening** may be recommended for patients with ongoing exposure risk while on certain therapies	A negative test is mandatory before initiating these immunosuppressive drugs
Hepatitis B and C	**Prior to starting any biologic** or targeted synthetic DMARD	Generally **one-time screening** unless new risk factors for infection arise	Treatment initiation must be delayed if active infection is found
Interstitial Lung Disease	**At baseline** (initial diagnosis) and whenever **new or persistent pulmonary symptoms** (e.g., dry cough, unexplained shortness of breath) arise	No routine periodic screening for asymptomatic patients. Follow-up PFT/HRCT as indicated by symptoms or disease progression	Highly symptom-driven, but baseline PFTs are often obtained in high-risk patients (e.g., those with Anti-CCP positive RA)
Malignancy	Should follow **general population guidelines** (e.g., mammography, colonoscopy) plus increased vigilance	**Annual skin checks** are recommended, especially for those on TNF inhibitors (due to a slight increased risk of non-melanoma skin cancer)	Screening is based on age/sex

Comorbidity	When to Initiate Screening	Recommended Frequency	Key Consideration
Mental Health (Depression/Anxiety)	**At the initial visit** and **periodically** during routine follow-up visits (e.g., annually or when disease activity flares)	**Every 6–12 months** using brief, validated screening tools (e.g., PHQ-2 or PHQ-9)	Important for assessing overall disease impact and adherence to therapy

Abbreviations: ACR, American College of Rheumatology; CVD, Cardiovascular Disease; BP, Blood Pressure; DXA or DEXA, Dual-energy X-ray Absorptiometry; FRAX, Fracture Risk Assessment Tool; TB, Tuberculosis; CDC, Centers for Disease Control and Prevention; PFTs, Pulmonary Function Tests; HRCT, High-Resolution Computed Tomography; PHQ-9, Patient Health Questionnaire-9; DMARDs, Disease-Modifying Antirheumatic Drugs

Staging/Severity Matrix[23,24]

The **DAS28 (Disease Activity Score for 28 Joints)** and the **SDAI (Simplified Disease Activity Index)** are standardized, validated scoring systems used to measure the current disease activity and severity in inflammatory polyarthropathy. Other accepted structured disease assessments include the Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire (HAQ), Routine Assessment of Patient Index Data 3 (RAPID3), and Patient Activity Scale (PAS) II. See tables below.

Disease Activity Score - DAS28

Component	How the Data is Collected	Notes on Scoring
1. Tender Joint Count (TJC)	Physician counts the number of the 28 specified joints (shoulders, elbows, wrists, MCPs, PIPs) that are tender to the touch	Score is the raw count (0–28)
2. Swollen Joint Count (SJC)	Physician counts the number of the 28 specified joints that are visibly swollen	Score is the raw count (0–28)
3. Patient Global Assessment (PGA)	The patient rates their overall disease activity on a visual analogue scale (VAS) or numerical rating scale (NRS)	Score is usually 0–100mm or 0–10
4. Acute Phase Reactant	Lab measurement of systemic inflammation	Uses either **ESR** (Erythrocyte Sedimentation Rate) or **CRP** (C-Reactive Protein)
5. Calculation	The four values are entered into a proprietary formula	Use online calculator to input data into the formula
6. Interpretation	The final score falls into a specific category: ranging from <2.6 in remission to >5.1 with high disease activity	Re <2.6: Remission (Very Good Control) 2.6–3.2: Low Disease Activity (Good Control). >3.2: Active Disease (May need medication change). >5.1: High Disease Activity (Needs careful monitoring/adjustment)

Simplified Disease Activity Index - SDAI

The SDAI is a simplified scoring method that uses a direct sum of five components, avoiding the complex logarithmic formula.

Component	How the Data is Collected	Notes on Scoring
1. Tender Joint Count (TJC)	Same 28-joint count as DAS28	Score is the raw count (0–28)
2. Swollen Joint Count (SJC)	Same 28-joint count as DAS28	Score is the raw count (0–28)
3. Patient Global Assessment (PGA)	Patient rates disease activity on a 0–10 scale	Score is 0–10
4. Physician Global Assessment (PhGA)	Physician rates disease activity on a 0–10 scale	Score is 0–10
5. C-Reactive Protein (CRP)	Lab value is used directly, typically standardized to a 0–10 scale (CRP in mg/dL)	Score is 0–10
6. Calculation	Sum the five components: SDAI = TJC + SJC + PGA + PhGA + CRP	Max possible score is 48
7. Interpretation	The final score falls into a specific category:	Interpret the result: • ≤3.3: Remission • ≤11: Low Disease Activity • >11 to ≤26: Moderate Disease Activity • >26: High Disease Activity Treatment Response: • Major response: Change of ≥17 points (or ≥21 for significant) • Moderate response: Change of ≥7 points (or 10-21 for moderate) • No response: Change ≤9 points

3. MEAT DOCUMENTATION ESSENTIALS

MONITOR: "**DAS28-CRP 4.6** (Moderate Activity, minimal change over 6 weeks). TJC 6/SJC 4. **CRP 18 mg/L** [date]. Home BP log averaging 148/92 on 2 agents. DXA scan T-score -2.8 (Hip). LFTs/CBC stable (Last checked [date])"

EVALUATE: "Reviewed TJC/SJC trend, confirms persistent synovitis across 6 joints. Anemia evaluation: Hgb 11.0g/dL, ferritin 165, TSAT 22%, consistent with anemia of chronic disease (D63.0) due to active RA. Cardiovascular risk evaluation: High, due to uncontrolled HTN and chronic inflammation"

ASSESS: "**Moderate Disease Activity** (DAS28 4.6, confirmed >3 months), rapid functional decline (HAQ increased 0.5 points in 3 months) despite full dose MTX. **Treatment failure** evident. Complicated by severe osteoporosis (M82.8) and uncontrolled hypertension (I10)"

TREAT: "Initiated prior authorization for **TNF inhibitor** (Adalimumab). Counseled on infection risk and need for pre-biologic testing. **Osteoporosis:** Started **Bisphosphonate** therapy weekly. **Hypertension:** Increased

dose of ACE inhibitor. Dietary counseling provided for low-sodium intake. Urgent referral to **Occupational Therapy (OT)** placed for joint protection"

Clinical Documentation Elements

Priorities	What to Document	Example
Specify Diagnosis	Use the specific inflammatory condition (HCC-bearing when applicable). Avoid nonspecific terms	**Inflammatory Polyarthropathy** (M06.4), **Rheumatoid Arthritis** (M05.9) or **Systemic Lupus Erythematosus** (M32.9) NOT "Chronic Arthritis"
Causal Relationships	Link the primary inflammatory condition to its key **comorbidities** and complications when present (e.g., bone loss, anemia)	**Osteoporosis secondary to inflammatory polyarthropathy** (M82.8) NOT "RA and Osteoporosis" as separate, unlinked problems
Include Current Data	Include the **current, objective measure of disease activity** reviewed during the encounter	**DAS28-CRP 4.6** (date) or **CRP 18mg/L** reviewed NOT "Inflammatory polyarthopathy is stable"
Acuity and Severity	Document the **acuity** (active vs. in remission) and **severity** using a standard scale	**Moderate Disease Activity** (DAS28 4.6) NOT "Arthritis in follow-up." Must reflect active management
Document Management	Adhere to **MEAT** (Monitor, Evaluate, Address/Assess, Treat). Demonstrate the complexity of care	**Treatment Failure** after 3 months of MTX, **Biologic initiated** (T). NOT simply listing medications

Reframing Common Documentation Shortcuts

Instead of…	Prefer documenting…	Why this supports care
"Stable arthritis"	"In remission; DAS28-CRP 2.4 (date)"	Anchors status to validated disease activity metric
"Switched medication"	"Persistent moderate activity (DAS28 4.8); biologic initiated due to MTX failure"	Documents rationale and escalation
"Osteoporosis and arthritis"	"Osteoporosis secondary to inflammatory polyarthropathy"	Links complication causally
"Monitoring labs"	"LFTs reviewed (date); stable, confirming MTX tolerance"	Demonstrates active safety monitoring

4. TREATMENT AND REFERRAL QUICK GUIDE

Therapy Escalation Criteria

Trigger	Action	Expected Benefit

Diagnose inflammatory polyarthropathy	**Start DMARD** First line: Methotrexate [MTX] Hydroxychloroquine (HCQ): Recommended for low disease activity or with MTX Sulfasalazine (SSZ): Can be used with MTX Leflunomide: Can be used in place of or with MTX	↓ ESR (if initially elevated) ↓ CRP (if initially elevated) Functional improvement self-reported by patient *Current guidelines emphasize composite disease activity scores (DAS28, CDAI, SDAI) and a treat-to-target approach aiming for remission or low disease activity rather than just laboratory markers alone*
Inadequate response at 3 month follow-up	**Add biologic agent** TNF inhibitor: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab. Other Biologics: Abatacept (T-cell blocker), Rituximab (B-cell blocker), Tocilizumab (IL-6 inhibitor) Consider short-term use of systemic glucocorticoids	
Adequate response at 3 month follow-up	Continue treatment	

Abbreviations: DMARD, Disease-Modifying Antirheumatic Drug; MTX, Methotrexate; HCQ, Hydroxychloroquine; SSZ, Sulfasalazine; ESR, Erythrocyte Sedimentation Rate; CRP, C-Reactive Protein; TNF inhibitor, Tumor Necrosis Factor inhibitor; IL-6 inhibitor, Interleukin-6 inhibitor

Inflammatory Polyarthropathy Treatment Options[10,25–27]

Pharmaceuticals	Ongoing Monitoring via System Review and Physical Examination	Ongoing Laboratory Monitoring and Other Testing
Salicylates, NSAIDs	Dyspepsia, nausea/vomiting, abdominal pain, edema, blood pressure	CBC and complete metabolic panel (electrolytes, creatinine, albumin, transaminases) every 6 months
Glucocorticoids	Mood, weight gain, visual changes, weakness, polyuria, polydipsia, edema, infection, blood pressure	Diabetes screening, lipids, bone mineral density testing
Hydroxychloroquine	Visual change, skin color change, paresthesia	Ophthalmologic evaluation for retinal toxicity
Sulfasalazine	Headache, nausea, diarrhea, photosensitivity, symptoms of myelosuppression, hepatotoxicity, rash	CBC, aminotransferases, and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks
Methotrexate	Stomatitis, alopecia, diarrhea, nausea/vomiting, flu-like symptoms, shortness of breath, symptoms of myelosuppression, hepatotoxicity,	CBC, aminotransferases, and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks

Pharmaceuticals	Ongoing Monitoring via System Review and Physical Examination	Ongoing Laboratory Monitoring and Other Testing
	infection, lymph node swelling, pregnancy	
Leflunomide	Nausea/vomiting, diarrhea, shortness of breath, paresthesia, hepatotoxicity, weight loss, blood pressure, pregnancy	CBC, aminotransferases, and creatinine every 2 to 4 weeks for the first 3 months or after increasing the dose, every 8 to 12 weeks for months 3 to 6, then every 12 weeks
Minocycline	Hyperpigmentation, dizziness, falls	None after baseline
Azathioprine	Diarrhea, nausea/vomiting, symptoms of myelosuppression, infection	CBC and platelet count every 1 to 2 weeks with changes in dose, every 1 to 3 months thereafter
TNF Inhibitors (e.g., etanercept, infliximab, adalimumab)	Infection, malignancy, demyelination, congestive heart failure, autoimmune phenomenon	No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)
IL-6 Inhibitors (e.g., tocilizumab and sarilumab)	Infection, symptoms of myelosuppression (PMNs and platelets), demyelination, hepatotoxicity, gastrointestinal perforations	CBC with differential (neutrophils) and LFTs every 4 to 8 weeks until stable, then every 3 months. Lipids 4 to 8 weeks after starting therapy, then every 6 months
Rituximab	Infection, PML, symptoms of neutropenia	CBC every 2 to 4 months
Abatacept	Infection, COPD exacerbation, malignancy	No routine laboratory monitoring (unless also receiving a concurrent conventional DMARD)
JAK Inhibitors (e.g., tofacitinib, baricitinib, and upadacitinib)	Infection, zoster, symptoms of myelosuppression, hepatotoxicity, malignancy, gastrointestinal perforation	CBC with differential, creatinine, LFTs (transaminases, albumin, bilirubin) every month for 3 months, then every 3 months; lipids 6 to 8 weeks after drug start

Abbreviations: CBC: complete blood cell count (hematocrit, hemoglobin, white blood cell count, including differential white blood cell count and platelet counts); COPD, chronic obstructive pulmonary disease; DMARD: disease-modifying antirheumatic drug; IL-6: interleukin 6; JAK: Janus kinase; LFTs: liver function tests; NSAIDs: nonsteroidal antiinflammatory drugs; PML: progressive multifocal leukoencephalopathy; PMNs: polymorphonuclear leukocytes; TB: tuberculosis; TNF: tumor necrosis factor

Non-Rx Treatment Documentation[28]

Reviewed pain/stiffness patterns and medication timing. Education provided on **joint protection techniques** (e.g., using larger joints for lifting, avoiding tight gripping). **Energy conservation and pacing** strategies discussed to manage fatigue. Recommended **low-impact exercises** (e.g., swimming, cycling) and reviewed proper warm-up techniques. Referred to **Occupational Therapy (OT)** for formal functional evaluation and training in Activities of Daily Living (ADLs) (Medicare covers OT under Part B). Patient

provided with **a pain and stiffness diary, instructed to track morning symptoms, and advised to call** if a new monoarthritis flare occurs.

When to Refer[17,28,29]

Specialty	URGENT (<2 Weeks)	ROUTINE (4-8 Weeks)
Rheumatology	Suspected new-onset arthritis with poor prognostic factors (e.g., high-titer RF/Anti-CCP, erosions on X-ray). Acute, severe monarthritis where septic arthritis cannot be ruled out	Failure to reach treatment target (Remission/LDA) after 3-6 months of first-line therapy
Ophthalmology	New onset Uveitis/Iritis (acute red, painful eye). Acute, severe visual changes	Patients on long-term Hydroxychloroquine for routine retinal toxicity screening
Pulmonology	New or rapidly worsening dyspnea (shortness of breath) or persistent cough suggestive of Interstitial Lung Disease (ILD)	Workup of suspected mild/chronic lung nodules or pulmonary hypertension
Gastroenterology	Acute, severe GI bleeding (from NSAIDs/steroids). Severe, new-onset IBD symptoms (bloody diarrhea, weight loss)	Evaluation of chronic GI symptoms potentially related to Enteropathic Arthritis
Infectious Disease	Acute septic arthritis or complex opportunistic infection while on immunosuppressive therapy (e.g., Biologics)	Pre-treatment screening/consult for patients with complex history (e.g., prior TB, chronic viral hepatitis) before starting a Biologic/JAK inhibitor
Orthopedic Surgery	Acute, severe tendon rupture or rapidly destructive joint disease requiring immediate stabilization	Evaluation for chronic, end-stage joint destruction (e.g., hip/knee) requiring elective total joint replacement
Physical/Occupational Therapy (PT/OT)	Acute, severe functional decline limiting essential daily activities (e.g., inability to transfer safely)	Routine referral for all patients with established disease and measurable functional limitations (HAQ-DI score of $\geq$1)

Abbreviations: RA, Rheumatoid Arthritis; RF, Rheumatoid Factor; Anti-CCP, Anti-Cyclic Citrullinated Peptide; LDA, Low Disease Activity; NSAIDs, Nonsteroidal Anti-inflammatory Drugs; IBD, Inflammatory Bowel Disease; GI, Gastroenterology; ILD, Interstitial Lung Disease; TB, Tuberculosis; JAK inhibitor, Janus Kinase inhibitor; PT, Physical Therapy; OT, Occupational Therapy; HAQ-DI, Health Assessment Questionnaire-Disability Index

Follow-up Timing[26,29]

- **High Activity (DAS28 >5.1):** Every 1 to 3 Months
- **Moderate Activity (DAS28 3.2 – 5.1):** Every 3 months
- **Low Activity (DAS28 2.6 – 3.2):** Every 4 to 6 Months
- **Remission (DAS28 <2.6):** Every 6 to 12 Months

Treatment Initiation/Change: When a **new DMARD or a biologic agent is started or the dose is significantly increased**, safety lab monitoring (CBC, LFTs) often requires follow-up visits or lab **checks every 4 to 8 weeks initially.** This ensures the drug is tolerated and not causing organ toxicity (e.g., liver or bone marrow suppression).

Established Therapy: Once the disease is in stable remission and the drug regimen is well-tolerated, the follow-up interval is extended to the 6-12 month range.

Patient Education and Adherence[25,30]

Documentation: "Educated on avoiding over-the-counter NSAIDs (ibuprofen, naproxen) unless approved, due to risks of GI bleeding and renal toxicity. Reviewed Methotrexate (MTX) dosing schedule (weekly) and importance of Folic Acid supplementation. Educated on recognizing symptoms of myelosuppression (fatigue, fever) and hepatotoxicity (jaundice, dark urine). Counselled on energy conservation and joint protection techniques for ADLs. Provided written RA self-management and medication risk materials in the patient's language. Patient demonstrated understanding of weekly MTX dosing and agreed to a daily pain/stiffness diary for adherence and symptom tracking."

Comorbidity Management

Contraindications

Drug	Complete Contraindication
Methotrexate (MTX)	**Pregnancy/Breastfeeding** (highly teratogenic). **Significant Liver Disease** (e.g., cirrhosis, chronic active hepatitis). **Significant Renal Impairment** (creatinine clearance too low). **Active Alcoholism**
Leflunomide	**Pregnancy/Breastfeeding**. **Significant liver disease**
Sulfasalazine	Known **Sulfa allergy** or **Salicylate allergy**
TNF Inhibitors (e.g., Adalimumab, Infliximab)	**Active, Serious Infection** (e.g., active sepsis, pyelonephritis, deep-seated infection). **Active Tuberculosis (TB)**. **Severe Congestive Heart Failure (CHF)** (NYHA Class III/IV)
JAK Inhibitors (e.g., Tofacitinib, Baricitinib)	**Active, Serious Infection**. **Active Tuberculosis**. **Absolute Lymphocyte Count** too low (risk of immunosuppression)
Rituximab	**Active, Serious Infection**

Abbreviations: MTX, Methotrexate; TB, Tuberculosis; CHF, Congestive Heart Failure; NYHA, New York Heart Association; TNF Inhibitors, Tumor Necrosis Factor Inhibitors; JAK Inhibitors, Janus Kinase Inhibitors

Chronic Kidney Disease (CKD)[26,31,32]

Treatment/Class	CKD Consideration	Dose Adjustment/Action
Methotrexate (MTX)	Primarily excreted by the kidneys; risk of severe toxicity and myelosuppression if clearance is poor	**Reduced dose** based on estimated GFR (e.g., often contraindicated or used with extreme caution if GFR is <30 mL/min)
NSAIDs (e.g., Ibuprofen)	Should generally be avoided; they can cause AKI and accelerate CKD progression	**Avoid or use lowest dose for shortest duration** only if GFR is stable and above a safe threshold Avoid in stage 3 or higher Avoid if GFR is <30 mL/min
Leflunomide	Metabolized by the liver, but active metabolite is highly protein-bound; generally requires careful monitoring	**Caution/Avoidance** in ESRD/Stage 5 CKD
Glucosamine/Chondroitin	Risk of potassium accumulation with some formulations	**Caution** with certain supplements
Abbreviations: MTX, Methotrexate; GFR, Glomerular Filtration Rate; NSAIDs, Nonsteroidal Anti-inflammatory Drugs; AKI, Acute Kidney Injury; CKD, Chronic Kidney Disease; ESRD, End-Stage Renal Disease		

Hepatic Impairment[26]

Treatment/Class	Liver Consideration	Dose Adjustment/Action
Methotrexate (MTX)	Can cause or worsen liver fibrosis/cirrhosis	**Contraindicated** in severe liver disease (e.g., cirrhosis, active hepatitis). Dose reduction or switch required if LFTs elevate significantly during treatment
Leflunomide	Hepatotoxic risk	**Contraindicated** in severe liver disease. Requires frequent LFT monitoring
Biologics/JAK Inhibitors	While generally safer than MTX, requires baseline screening for Hepatitis B/C	**Pre-treatment viral screening** (Hepatitis B/C) is mandatory; treatment may need to be postponed or managed in consultation with an Infectious Disease specialist
Abbreviations: Abbreviations: MTX, Methotrexate; LFTs, Liver Function Tests; DMARDs, Disease-Modifying Antirheumatic Drugs; JAK Inhibitors, Janus Kinase Inhibitors		

Cardiovascular Disease & Congestive Heart Failure[33,34]

Treatment/Class	CVD/CHF Consideration	Dose Adjustment/Action
TNF Inhibitors	Can potentially worsen heart failure	**Contraindicated** in severe CHF (NYHA Class III/IV). Caution required in moderate CHF

Treatment/Class	CVD/CHF Consideration	Dose Adjustment/Action
JAK Inhibitors	Some studies suggest an increased risk of venous thromboembolism (VTE) and major adverse cardiovascular events (MACE)	**Caution** in patients with high baseline CVD risk. The lowest effective dose should be used
NSAIDs	Can cause fluid retention, worsening hypertension and CHF; increases risk of MACE	**Avoid** in severe CHF/uncontrolled HTN. Use lowest dose for shortest duration if necessary
Corticosteroids	**High Risk.** Increases fluid retention, hypertension, and accelerates general cardiovascular risk (MACE, atherosclerosis)	Avoid or use the absolute minimum dose necessary for the underlying condition (e.g., severe RA, COPD)

Abbreviations: CHF, Congestive Heart Failure; NYHA, New York Heart Association (used for grading heart failure severity); VTE, Venous Thromboembolism; MACE, Major Adverse Cardiovascular Events; CVD, Cardiovascular Disease; HTN, Hypertension; NSAIDs, Non-Steroidal Anti-inflammatory Drugs; JAK inhibitors, Janus Kinase inhibitors; TNF inhibitors, Tumor Necrosis Factor inhibitors

Hematologic Comorbidities[26]

Treatment/Class	Hematologic Consideration	Dose Adjustment/Action
DMARDs/JAK Inhibitors	Risk of myelosuppression (leukopenia, thrombocytopenia)	**Withhold or reduce dose** if blood counts drop below critical thresholds. Requires regular **CBC monitoring**
Rituximab	Can cause significant B-cell depletion and lymphopenia	**Dose adjusted** based on patient factors, and pre-treatment screening for infections is essential

Abbreviations: DMARDs, Disease-Modifying Antirheumatic Drugs; JAK Inhibitors, Janus Kinase Inhibitors; CBC, Complete Blood Count

Cost-Smart Options[35,36]

Cost savings for biosimilars offer significant cost savings, often around **20-40%, occasionally up to 60%**.

Brand/High-Cost Agent	Generic/Alternative Cost-Smart Option	Expected Monthly Savings (Approx)*
Humira (Adalimumab) (Biologic)	**Adalimumab Biosimilar** (e.g., Hyrimoz, Amjevita, Hadlima)	**$1,000 - $3,000+**
Enbrel (Etanercept) (Biologic)	**Etanercept Biosimilar** (e.g., Erelzi)	**$1,000 - $3,000+**
Orencia (Abatacept) (Biologic)	**Methotrexate (MTX)** (First-line anchor therapy)	**$4,000 - $8,000+**
Xeljanz (Tofacitinib) (JAK Inhibitor)	**Methotrexate (MTX) generic** or **Sulfasalazine**	**$1,500 - $3,500+**

Brand/High-Cost Agent	Generic/Alternative Cost-Smart Option	Expected Monthly Savings (Approx)*
Cimzia/Simponi (Biologics)	**Infusion Biologic** (e.g., Infliximab biosimilar)	**$500 - $2,000**
High-Dose Oral NSAIDs (OTC/Rx)	**Acetaminophen** (If inflammation is minimal)	**$20 - $100**

Quality Metrics Tie-In[28,37,38]

Measure (HEDIS/CMS Star Domain)	Target	Impact (Clinical & Quality Program)
Medication Adherence for DMARDs (Implied) (HEDIS/Star Part D)	≥80% Proportion of Days Covered - PDC)	Ensures consistent use of DMARDs (like MTX, HCQ, SSZ, or Biologics) necessary for achieving remission and preventing irreversible joint damage
Use of High-Risk Medication (HRM) in the Elderly (Medicare Star & HEDIS)	≤15 days of concurrent or long-term inappropriate use (Specific to NSAIDs)	Reduces risks of severe GI bleeding, cardiovascular events (MACE), and acute kidney injury (AKI) from inappropriate NSAID use
Management: DMARD Therapy (Older HEDIS/State-Level Measure)	≥85% of new arthritis diagnoses initiate DMARD therapy within 6 months of diagnosis	**Time is Joint**. Ensures early care adheres to the "Treat-to-Target" strategy, which is crucial for preventing joint destruction
Controlling Blood Pressure (HTN) (HEDIS/Star Part C)	≥70% of patients with HTN have BP controlled (<140/90 mmHg)	**Triple weighted. Contributes to Star Rating/MIPS.** Directly addresses the heightened **Cardiovascular Risk** associated with chronic inflammatory diseases
Osteoporosis Management in Women Who Had a Fracture (Star Part C)	≥60% of women aged 67–85 who had a fracture received appropriate pharmacotherapy	Ensures management of a major complication of chronic inflammation and **glucocorticoid** use, a key component of polyarthritis care

Abbreviations: DMARDs, Disease-Modifying Antirheumatic Drugs; HEDIS, Healthcare Effectiveness Data and Information Set; PDC, Proportion of Days Covered; MTX, Methotrexate; HCQ, Hydroxychloroquine; SSZ, Sulfasalazine; HRM, High-Risk Medication; NSAIDs, Nonsteroidal Anti-inflammatory Drugs; GI, Gastrointestinal; MACE, Major Adverse Cardiovascular Events; AKI, Acute Kidney Injury; HTN, Hypertension; BP, Blood Pressure; MIPS, Merit-based Incentive Payment System

5. CODING REMINDERS AND CASE EXAMPLES[39]

Documentation Specificity

Document diagnosis, activity, distribution, and management clearly:

- **Etiology/Type**: Specify the inflammatory diagnosis (e.g., inflammatory polyarthropathy M06.4, rheumatoid arthritis M05.x). Avoid nonspecific labels (e.g., "chronic polyarthritis")
- **Activity status**: State whether disease is active or in remission
- **Disease activity score**: Include validated composite measure with date (e.g., DAS28-CRP 4.2; CDAI documented)
- **Joint involvement**: Specify distribution (polyarticular) or exact site when applicable (eg, right hand involvement)
- **Comorbid conditions**: Link secondary conditions causally when present (e.g., osteoporosis secondary to inflammatory polyarthropathy M82.8)
- **Therapeutic management**: Document treatment course, including prior-line therapy response and rationale for escalation (eg, MTX trial failure; biologic initiated)

Annual Clinical Review and Confirmation

Confirm disease activity, severity, and ongoing management:

- **Annual review**: Inflammatory polyarthropathy should be reassessed once per calendar year via face-to-face or synchronous audio-video encounter, with MEAT documented by 12/31
- **Visit modality**: In-person or video telehealth encounters qualify when disease activity and management are addressed

Good Documentation is Comprehensive Coding

If documentation lacks...	Strengthen it by documenting...
Objective inflammation data	Number and location of involved joints; imaging evidence (eg, erosions on X-ray)
Composite activity score	Validated score such as DAS28 or CDAI with calculated value and date
Serologic or trend data	RF, Anti-CCP, ANA, CRP/ESR results and relevant serial trends
Therapy escalation rationale	Dates, doses, and documented response or intolerance to prior agents (eg, MTX, leflunomide, sulfasalazine) before biologic initiation

EHR Tips

- **Auto-Calculation of DAS28/CDAI**
- **Alert:** Biologic safety screening when a Biologic or JAK Inhibitor order is placed if TB (QuantiFERON/PPD) or Hepatitis B/C screening labs are missing or outdated (e.g., >12 months old)
- **KFRE calculator** embedded for referral timing
- **Auto-prompt** for "etiology + stage" when adding CKD to the problem list (reduces unspecified N18.30 coding)

Brief Case Examples

SUCCESS: "78-year-old female with diabetes with complications, CKD3b, and long-standing inflammatory polyarthropathy presenting with a flare and requesting a biologic initiation (M06.4). Currently

demonstrating **High Disease Activity (DAS28-CRP 5.8)**; TJC 12/28, SJC 9/28. Failed Methotrexate (20mg subQ X 8 months) due to inefficacy and Leflunomide (20mg X 4 months) due to liver enzyme elevation → Captures HCC 37 (0.166) + HCC 328 (0.127) + HCC 93 (0.617) X $10,402.34 = $9466.13/year

PITFALL: "Inflammatory Polyarthropathy, needs MTX." No Tender/Swollen Joint Counts (TJC/SJC) or ESR/CRP documented. → Audit fail, loses 0.617 X 10,402.34 = $6418.24
FIX: "New diagnosis of Inflammatory Polyarthropathy, (M06.4). Patient meets 2010 ACR criteria: TJC 8/28, SJC 6/28. Active inflammation confirmed by CRP 4.5mg/L. Initiate Methotrexate 15 mg weekly, with plan to escalate to 20mg in 4 weeks."

REFERENCES

1. Alpay-Kanıtez N, Çelik S, Bes C. Polyarthritis and its differential diagnosis. *Eur J Rheumatol*. 2019;6(4):167-173. doi:10.5152/eurjrheum.2019.19145
2. Zhu JR, Galivanche AR, Gouzoulis MJ, et al. International Classification of Diseases Coding for Inflammatory Arthritides. *JAMA Netw Open*. 2024;7(4):e246544. doi:10.1001/jamanetworkopen.2024.6544
3. Fallon EA, Boring MA, Foster AL, et al. Prevalence of Diagnosed Arthritis — United States, 2019–2021. *MMWR Morb Mortal Wkly Rep*. 2023;72(41):1101-1107. doi:10.15585/mmwr.mm7241a1
4. Poudel P, Lappin SL. Inflammatory Arthritis. In: *StatPearls*. StatPearls Publishing; 2025. Accessed December 8, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507704/
5. Lo T, Parkinson L, Cunich M, Byles J. Cost of arthritis: a systematic review of methodologies used for direct costs. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(1):51-65. doi:10.1586/14737167.2016.1126513
6. Foster ZJ, Day AL, Miller J. Polyarticular Joint Pain in Adults: Evaluation and Differential Diagnosis. *Am FamPhysician*.2023;107(1):42-51. https://www.aafp.org/pubs/afp/issues/2023/0100/polyarticular-joint-pain-adults.html
7. Pujalte GG, Albano-Aluquin SA. Differential diagnosis of polyarticular arthritis. *Am Fam Physician*. 2015;92(1):35-41. https://www.aafp.org/pubs/afp/issues/2015/0701/p35.html
8. Siva C, Larson EC, Barnett M. Rational Use of Blood Tests in the Evaluation of Rheumatic Diseases. *Mo Med*. 2012;109(1):59-63. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179786/
9. Richie AM, Francis ML. Diagnostic approach to polyarticular joint pain. *Am Fam Physician*. 2003;68(6):1151-1160. https://www.aafp.org/pubs/afp/issues/2003/0915/p1151.html
10. Akhondi H, Blum MA, Gupta N. Polyarticular Arthritis. In: *StatPearls*. StatPearls Publishing; 2025. Accessed December 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK537170/
11. Bombei B, Freilich A, Larsen H. Approach to Polyarthritis for the Primary Care Physician. *Osteopath Fam Physician*. 2018;10(5):24-31. doi:10.1016/j.osfp.2018.08.003
12. Kumar A. How to investigate new-onset polyarthritis. *Best Pract Res Clin Rheumatol*. 2014;28(6):844-859. doi:10.1016/j.berh.2015.04.002
13. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. *Nat Rev Rheumatol*. 2016;12(6):335-343. doi:10.1038/nrrheum.2016.52
14. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. *Arthritis Res Ther*. 2014;16(2):R61. doi:10.1186/ar4498
15. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract Res Clin Rheumatol*. 2017;31(1):3-18. doi:10.1016/j.berh.2017.08.003
16. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. *Arthritis Rheum*. 2011;63(3):633-639. doi:10.1002/art.30155
17. Handa R. Emergencies in Rheumatology. In: *Clinical Rheumatology*. Springer; 2021:227-233. doi:10.1007/978-981-15-8323-0_18

18. Pianarosa E, Roach P, Barber CE, et al. Deciding to attend the emergency department: experiences of patients with inflammatory arthritis. *J Rheumatol*. 2024;51(10):1015-1022. doi:10.3899/jrheum.2024-0046
19. Klinkhoff A. Rheumatology: 5. Diagnosis and management of inflammatory polyarthritis. *CMAJ*. 2000;162(13):1833-1838. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1231375/
20. Havens E. Comorbid Arthritis Is Associated With Lower Health-Related Quality of Life in Older Adults With Other Chronic Conditions, United States, 2013–2014. *Prev Chronic Dis*. 2017;14:160495. doi:10.5888/pcd14.160495
21. Ursum J, Nielen MM, Twisk JW, et al. Increased risk for chronic comorbid disorders in patients with inflammatory arthritis: a population based study. *BMC Fam Pract*. 2013;14(1):199. doi:10.1186/1471-2296-14-199
22. Margaretten ME, Katz P, Schmajuk G, Yelin E. Missed Opportunities for Depression Screening in Patients with Arthritis in the United States. *J Gen Intern Med*. 2013;28(12):1637-1642. doi:10.1007/s11606-013-2541-y
23. Schally J, Brandt HC, Brandt-Jürgens J, et al. Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study. *Ther Adv Musculoskelet Dis*. 2022;14. doi:10.1177/1759720X221114107
24. Pisaniello HL, Whittle SL, Lester S, et al. Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. *BMC Rheumatol*. 2022;6:67. doi:10.1186/s41927-022-00299-3
25. Ledingham J, Snowden N, Ide Z. Diagnosis and early management of inflammatory arthritis. *BMJ*. 2017;358:j3248. doi:10.1136/bmj.j3248
26. Singh S, Mehra S. Approach to Polyarthritis. *Indian J Pediatr*. 2010;77(9):1005-1010. doi:10.1007/s12098-010-0163-5
27. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care Res*. 2020;72(6):744-760. doi:10.1002/acr.24180
28. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123. doi:10.1002/art.41752
29. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis*. 2010;69(6):964-975. doi:10.1136/ard.2009.126532
30. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. *Ann Rheum Dis*. 2017;76(6):948-959. doi:10.1136/annrheumdis-2016-210602
31. National Kidney Foundation. Pain Medications for CKD: Risks, Safety, and Alternatives. Accessed December 15, 2025. https://www.kidney.org/kidney-topics/pain-medicines-and-kidney-disease
32. Patel SS, Kimmel PL, Singh A. New Clinical Practice Guidelines for Chronic Kidney Disease: A Framework for K/DOQI. *Semin Nephrol*. 2002;22(6):449-458. doi:10.1053/snep.2002.35973
33. Hansildaar R, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. *Lancet Rheumatol*. 2021;3(1):e58-e70. doi:10.1016/S2665-9913(20)30221-6
34. van Sijl AM. Cardiovascular Risk in Inflammatory Arthritis. Doctoral dissertation. Published online 2014. https://dare.ubvu.vu.nl/handle/1871/51322
35. Persaud V, Bernstein R, Wertheimer A. Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations. *J Pharm Pract*. 2025. doi:10.1177/08971900251394782
36. American College of Rheumatology. Biosimilars. Accessed December 15, 2025. https://rheumatology.org/patients/biosimilars
37. Foley KA, Foster SA, Meadows ES, Baser O, Long SR. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Med Care*. 2007;45(9):902-906. doi:10.1097/MLR.0b013e318074ce7a

38. Singer GM, Izhar M, Black HR. Guidelines for Hypertension: Are Quality-Assurance Measures on Target? *Hypertension*. 2004;43(2):198-202. doi:10.1161/01.HYP.0000114697.12750.d2
39. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. *Health Care Financ Rev*. 2004;25(4):119-141. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194896/

Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to coding guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.